Drug intelligence / Profile preview

RT201

Development stage: Phase 1
Lead developer: Suzhou Ruotai Pharmaceutical Technology
Modality: Vaccines & Immunotherapeutics, Cell Therapies
Administration: Intravenous

Overview

RT201 is a tumor antigen-specific macrophage tumor vaccine developed as a cell therapy for the treatment of advanced malignant tumors, with a primary focus on advanced cervical carcinoma. The therapy involves screening for tumor-specific antigens, HLA typing, blood sample collection, cell separation and culture, and reinfusion of modified cells into the patient. This individualized approach aims to stimulate an immune response against cancer cells by leveraging macrophages that are specific to tumor antigens. Clinical trials are ongoing to evaluate its safety and efficacy in patients with advanced cancers[1][3][4].

Other names: Tumor Antigen-specific Macrophage Tumor Vaccine

Targets

Neoantigen (Patient-specific tumor-associated antigen peptides presented by HLA class I molecules)

Beyond the preview

Go deeper on RT201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RT201.